IMPORTANCE Acute kidney injury (AKI) is a common and serious complication for pediatric cardiac surgery patients associated with increased morbidity, mortality, and length of stay. Current strategies focus on risk reduction and early identification because there are no known preventive or therapeutic agents. Cardiac surgery and cardiopulmonary bypass lyse erythrocytes, releasing free hemoglobin and contributing to oxidative injury. Acetaminophen may prevent AKI by reducing the oxidation state of free hemoglobin.
A cute kidney injury (AKI) occurs in approximately 25% of children admitted to intensive care units (ICUs). [1] [2] [3] [4] [5] [6] [7] [8] [9] Among pediatric ICU patients, AKI is associated with increased length of stay and consistently demonstrates odds ratios (ORs) exceeding 3 for mortality. 1, 2, [8] [9] [10] [11] [12] Among children who have cardiac surgery, rates of AKI are even higher, and AKI is associated with increased morbidity, mortality, and length of stay. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] To date, efforts to reduce the effect of AKI in pediatric patients are focused on early detection and risk reduction because there are no known preventive or therapeutic agents for AKI.
For children who undergo cardiac surgery, the necessary cardiopulmonary bypass (CPB) causes hemolysis, which together with the tissue damage from surgery and administration of packed red blood cells leads to high circulating levels of free hemoglobin in these patients. 27 ,28 Cell-free plasma hemoglobin has been associated with AKI after cardiac bypass in children. 29 Based on data from animal models and adults, it is hypothesized that free hemoglobin contributes to AKI through the oxidation of the central iron of the heme moiety to the highly reactive and nephrotoxic ferryl (Fe 4+ ) form.
30-32
This pathogenic mechanism for AKI illuminates a potential therapeutic agent. Acetaminophen, a well-established drug used for analgesia and fever reduction, is known to reduce the oxidation of free hemoglobin by preventing the oxidation of iron from Fe 3+ to Fe 4+ . 32, 33 The hemoreductant activity of acetaminophen derives from the structural similarity between the heme moiety of hemoglobin and the peroxidase moiety of cyclooxygenase. In recent years, acetaminophen has been increasingly used after surgery in children to reduce opioid exposure.
The primary objective of this study was to test the hypothesis that acetaminophen exposure in the first 48 hours after cardiac surgery is associated with reduced risk of AKI in children. To test this hypothesis, we performed a retrospective observational study of children who had cardiac surgery in a primary cohort from the Monroe Carell Jr Children's Hospital at Vanderbilt, and we validated our findings in a second independent cohort from Duke Children's Hospital.
Methods

Population and Electronic Health Record Data Extraction
This study was reviewed and approved by the institutional review boards of Vanderbilt University Medical Center, Nashville, Tennessee, and Duke University, Durham, North Carolina. Written informed consent was obtained from parents or guardian, as well as written assent from study participants as appropriate by age. Inclusion criteria for the primary cohort were cardiac surgery at the children's hospital between July 1, 2008, and June 1, 2016, and age older than 28 days. Exclusion criteria were postoperative extracorporeal membrane oxygenation (because this may include renal replacement therapy and thus affect serum creatinine values) and absence of either the baseline or postoperative serum creatinine measurements to determine AKI status. If individuals had multiple cardiac surgical procedures, data from only the first surgery were included. After the primary cohort was analyzed, a second cohort was assembled to determine if these findings were unique to the institution or if they could be replicated in an independent validation cohort. Inclusion criteria for the validation cohort were the same as for the primary cohort, with the exception that the study inclusion dates were June 25, 2013, to March 29, 2016. All study data, including demographic, laboratory, medication administration, and administrative data, were extracted from electronic health record data sources. Medications administered in the first 48 postoperative hours were categorized as high-risk nephrotoxins (eg, aminoglycosides, ketorolac tromethamine, and tacrolimus), moderate-risk nephrotoxins (eg, loop diuretics, enalapril maleate, and trimethoprim-sulfamethoxazole [eTable 1 in the Supplement]), or nonnephrotoxins. Postoperative hypotension was defined using the systolic blood pressure measurements documented in the first 48 postoperative hours, irrespective of any vasopressor support. Hypotension was defined as one or more systolic blood pressures lower than 70 mm Hg plus 2 times the age in years if 10 years or younger and lower than 90 mm Hg if older than 10 years. 34 
Exposure and Outcome Definitions
Exposure was defined as dichotomous exposure to acetaminophen for the initial analysis and then the cumulative weightadjusted intravenous, enteral, and/or rectal acetaminophen dose (in milligrams per kilogram), alone or in combination with other medications, received in the first 48 hours after surgery. Individuals were also categorized as those receiving no acetaminophen or the lowest (<40 mg/kg), middle (40-80 mg/kg), or highest (>80 mg/kg) doses of acetaminophen. The AKI outcome was defined by change in serum creatinine values. Baseline serum creatinine measurements were defined as the lowest obtained in the 28 days before surgery. Postoperative serum creatinine measurements were defined as those obtained in the 7 days after surgery. Acute kidney injury was defined solely using the creatinine criteria because reliable urine output data are not available for all pediatric inpatients 35 and accurate height measurements were not consistently available among pediatric inpatients for estimated glomerular filtration rate. Individuals were classified as having AKI using Kidney Disease: Improving Global Outcomes (KDIGO) 7 serum creatinine criteria if any postoperative serum creatinine measurement increased by 0.3 mg/dL or more
Key Points
Question Does early postoperative acetaminophen exposure reduce the incidence of acute kidney injury in children who undergo cardiac surgery?
Findings In this cohort study, acetaminophen exposure in the first postoperative 48 hours was associated with a lower rate of acute kidney injury in pediatric patients who underwent cardiac surgery in primary and validation cohorts from 2 tertiary referral children's hospitals.
Meaning Postoperative use of acetaminophen may protect pediatric cardiac surgery patients from acute kidney injury.
from baseline (to convert creatinine level to micromoles per liter, multiply by 88.4) or was at least 1.5-fold more than the baseline in the first postoperative week. Those not meeting these criteria were classified as having no AKI. Acute kidney injury stage was determined for each AKI case using serum creatinine-based KDIGO definitions for stage 1 (≥0.3 mg/dL or 1.5-fold increase), stage 2 (2-fold increase), and stage 3 (≥4 mg/dL or 3-fold increase) based on the highest serum creatinine measurement in the 7 days after surgery. 38 The nonlinear association of age with AKI was modeled using the restricted cubic spline with 3 knots chosen at the 10th, 50th, and 90th percentiles. The same logistic regression model was used for both the primary and validation cohorts. Subgroup analyses were also done. First, logistic regression was performed for each cohort using the same methods and covariates as in the full cohort, excluding those individuals who had no acetaminophen exposure. In addition, a subgroup analysis was done by pooling individuals from both cohorts with a RACHS score of 3 or higher as an alternative method to account for variability in clinical status after surgery and likely degree of cell-free hemoglobin. For this analysis, the same logistic regression was performed as above, with the inclusion of clinical site as an additional covariate. Sensitivity analyses of unmeasured confounding were also performed (see the eAppendix in the Supplement). Multiple imputation was performed based on 10 completed data sets by applying predictive mean matching to handle missing data for 
Statistical Analysis
Results
Study Cohorts
The primary cohort included 666 individuals with baseline and postoperative serum creatinine measurements. Half of them were female, and half met criteria for AKI ( 
AKI and Acetaminophen Exposure
In the primary cohort, 72 (10.8%) had no acetaminophen exposure in the first 48 hours after surgery. The incidence of AKI was higher among those with no acetaminophen exposure than among those with acetaminophen exposure ( Figure 1A ). Comparing those with and without AKI, those without AKI had a significantly higher weight-adjusted acetaminophen dose in the first 48 hours after surgery compared with those with AKI ( Table 2) . Other variables significantly associated with AKI Figure 1B ). In the logistic regression analysis adjusting for age, CPB time, RDW, postoperative hypotension, nephrotoxin exposure, and RACHS score, acetaminophen exposure was protective against postoperative AKI, with an odds ratio (OR) of 0.86 (95% CI, 0.82-0.90) per each additional 10 mg/kg ( Figure 2 ). The association between continuous acetaminophen dose and adjusted odds for AKI is shown in Figure 3 . The patients who did not receive acetaminophen were younger and had longer CPB times, higher RDW, and more postoperative hypotension than those who received acetaminophen (eTable 4 in the Supplement). When subset analysis of the primary cohort was performed that excluded those with no acetaminophen exposure, acetaminophen remained protective against AKI (OR, 0.85 [95% CI, 0.80-0.90] per each additional 10 mg/kg; P < .001). We performed analyses to determine the sensitivity of our findings to unmeasured confounding. To make our findings statistically insignificant, an unmeasured confounder must have a minimum strength of association greater than 3.07 for both acetaminophen exposure and AKI (eTable 5 in the Supplement). For the validation cohort, 18 (5.4%) had no acetaminophen exposure, and there was no significant difference in AKI incidence between those with vs without acetaminophen exposure ( Figure 1A ). Comparing those with and without AKI, the median early postoperative acetaminophen dose was again higher among those without AKI than among those with AKI (Table 2 ). Younger age, longer CPB time, higher RDW, fewer high-risk nephrotoxins, and higher RACHS score were also associated with postoperative AKI. 
Pooled Subgroup Analysis
The pooled subgroup analysis included a total of 310 individuals with a RACHS score of 3 or higher from both clinical sites (237 from the primary cohort and 73 from the validation cohort). After adjusting for clinical site and the covariates included in the adjusted analyses of the full cohorts, acetaminophen dose (in milligrams per kilogram) in this 
Discussion
We present the finding of a protective association of acetaminophen against AKI in children who undergo cardiac surgery. The weight-adjusted total dose of acetaminophen given in the first 48 hours after surgery was inversely correlated with the incidence of AKI in the primary cohort using the dichotomous indicator of acetaminophen exposure and acetaminophen dose as a continuous variable and after adjusting for potential confounders, including age, CPB time, RDW, postoperative hypotension, nephrotoxin exposure, and RACHS score. Given this novel finding, we sought to confirm these observations in an independent data set, in which after adjusting for confounding variables that were not balanced across acetaminophen exposure groups the protective association of acetaminophen was again observed. Subgroup analyses of only those patients who received acetaminophen and those with a RACHS score of 3 or higher, representing more clinically homogeneous patients, yielded consistent results. The hypothesis that acetaminophen may be protective against AKI in the setting of cardiac surgery stemmed from several observations. In a case-control study 30 Cell-free hemoglobin was also associated with death in a retrospective observational study 31 of critically ill adults with sepsis, and acetaminophen exposure had a protective association with in-hospital mortality. In the subset of patients with no detectable plasma hemoglobin, there was no protective association of acetaminophen. This potential protective association of acetaminophen was evaluated prospectively in the Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis (ACROSS) trial. 33 That single-center, randomized, placebo-controlled trial of acetaminophen (1 g enterally every 6 hours for 3 days) found no difference in the primary end point, F2-isoprostane levels at day 3 (a measure of oxidative injury), or in hospital mortality, but it demonstrated that acetaminophen treatment affected secondary outcomes. Specifically, acetaminophen lowered F2-isoprostane levels at day 2 (24 vs 36 pg/mL, P = .047) and serum creatinine levels at day 3 (1.0 vs 1.3 mg/dL, P = .039). In another randomized trial 41 that included 700 adult ICU patients with fever, there was no difference in the primary outcome (ICU-free days) and no difference in the peak creatinine level in the first week after randomization. This negative result may indicate that acetaminophen has protective associations only in specific patient populations. There have been 2 pilot studies of the effect of acetaminophen on lipid peroxidation in patients undergoing CPB. In a prospective double-blind clinical trial, 42 before initiation of CPB, 60 adult patients were treated with 4 doses of intravenous acetaminophen over 24 hours (1 g for those >50 kg and 15 mg/kg for those <50 kg) or placebo. The primary outcome was oxidative stress, measured by plasma and urine F2-isoprostane and isofuran values. The acetaminophen treatment group had smaller increases in plasma isofuran concentrations compared with the placebo group, although there were no significant differences between groups in plasma F2-isoprostane levels, urinary markers of lipid peroxidation, or AKI. The second pilot study 43 randomized 30 children to be treated with 4 doses of intravenous acetaminophen (15 mg/kg for age ≥2 years and 12.5 mg/kg for age <2 years) or placebo, beginning before the start of CPB. As in the adult trial, acetaminophen attenuated increases in plasma isofuran levels, but there were no differences between the intervention and control groups in F2-isoprostane levels, AKI prevalence, AKI severity, or the AKI biomarker neutrophil gelatinaseassociated lipocalin (NGAL). There were several limitations to these pilot studies, including limited power because of the small number of participants and administration of 1 or more doses of acetaminophen before and during CPB, when circulating concentration of the drug may not have reached therapeutic levels because of hemodilution. These studies were not definitive in determining the potential role of acetaminophen to protect against AKI in patients with elevated cell-free hemoglobin.
Our results indicate a modest influence of acetaminophen on AKI. Specifically, we saw an approximately 10% reduction in AKI risk for each additional 10 mg/kg administered in the first 48 hours after surgery (one typical dose of acetaminophen). In the subgroup analysis of those with a RACHS score of 3 or higher, we observed a 14% reduction per 10 mg/kg of additional acetaminophen. The ideal dose for renal protection, while avoiding dose-related hepatotoxicity or other adverse events, has not been established. There may be several sources of interindividual variability contributing to differences in the exposure and response to acetaminophen in both adults and children. 44, 45 Further delineation of individualized therapeutic concentrations through a precision medicine approach may be required to maximize benefit and minimize risk of acetaminophen use.
Limitations
Our study has several limitations. This was a retrospective observational study. Therefore, causality between acetaminophen exposure and reduced incidence of AKI cannot be established. The apparent protective association of acetaminophen may be owing to residual confounding. Patients with acetaminophen exposure had fewer risk factors for AKI. Furthermore, these patients may have the most frequent serum creatinine testing, increasing AKI detection. We attempted to control for this potential confounding through multivariable analysis, adjusting for factors like age, CPB time, and RACHS score. Despite inclusion of these variables, acetaminophen remained protective. Our analyses of the sensitivity of the data to unmeasured confounding indicate that our data are robust. Those with AKI had fewer exposures to highly nephrotoxic drugs, which is an observation we have seen in multiple cohorts 3, 37 and may be owing to avoidance of these drugs among high-risk patients. Another limitation of our study stems from the definition of AKI. We used the consensus KDIGO definition based on serum creatinine values but did not define AKI based on urine output (which may be inaccurately represented in these retrospective data sets) or biomarkers, such as NGAL or cystatin C. 46 Our initial finding from one tertiary referral center was validated in independent data from a second tertiary referral center. However, these results may not be generalizable to institutions with a different patient mix, operative procedures, and postoperative care.
Conclusions
In 2 independent cohorts of children undergoing cardiac surgery, we observed a dose-dependent inverse association between postoperative receipt of acetaminophen and development of AKI. Taken together with other retrospective and prospective studies showing protective associations of acetaminophen against AKI in several conditions associated with release of cell-free hemoglobin, these findings provide a compelling rationale to justify prospective evaluation of acetaminophen for prevention of AKI in children undergoing CPB. 
Background
In any retrospective observational study, a causal link between the exposure and the outcome cannot be definitively proven. In our study, we observed an association between acetaminophen exposure and reduced risk of the outcome of acute kidney injury (AKI). In our analyses, we included subset analyses and adjustment for several covariates in an attempt to control for confounding, defined as factors that are associated with both the exposure and outcome, as confounding can lead to spurious associations. In our subset analyses and adjusted analyses, our observed association between acetaminophen exposure and reduced risk for AKI remained statistically significant. However, even after adjusting for potential observed confounders, there remains a possibility of residual confounding, as our covariates may fail to capture all factors associated with acetaminophen exposure and AKI.
Several methods have been developed to perform sensitivity analysis for the effects of unmeasured confounding. One approach is to calculate the bias due to hypothetical unmeasured confounders with various values of parameters, then correct for that bias to find the "true" association between the exposure and the outcome. Another approach is to find how strong an unmeasured confounder would have to be, in terms of its association to the exposure and the outcome, to "explain away" the observed association (i.e., to make the 95% confidence intervals (CI) include the null value, or 1). To address the possibility of unmeasured confounding in our study, we performed sensitivity analyses using both strategies. In these analyses, we sought to determine if bias-correcting our findings based on a hypothetical covariate with stronger association to both the exposure and the outcome than any of our ascertained covariates would render our findings statistically insignificant. Furthermore, we sought to define the strength of association to the exposure and outcome required for a hypothetical confounder to make our findings statistically insignificant.
Methods
For these sensitivity analyses, we defined acetaminophen exposure as a binary variable (i.e., no acetaminophen vs. any acetaminophen). We expressed the odds ratios (OR) for susceptibility to AKI based on the increased risk for those with no acetaminophen exposure [i.e., patients who received no acetaminophen were 2.63 (95% CI, 1.34-5.15) times more likely to develop AKI that those with ≥1 dose of acetaminophen, after adjusting for potential (measured) confounders such as age at surgery, surgery bypass time, the risk adjustment for congenital heart surgery (RACHS) score, 1 red cell distribution width, hypotension and use of nephrotoxic co-medications]. As a note, the observed OR of 2.63 for binary acetaminophen exposure is approximately equivalent to that for weightadjusted acetaminophen dose of 60 mg/kg, which is the dose halfway between the low and high dose acetaminophen thresholds in Figure 1 . In other words, patients who received ≥1 dose of acetaminophen were 62% (OR=0.38, 95% CI, 0.19-0.74) less likely to develop AKI compared to those who received no acetaminophen.
We used the methods developed by VanderWeels and Arah and Lin et al. to calculate the bias due to unmeasured confounders and correct the observed OR and 95% CI, where a bias-corrected 95% CI including the null value of 1 indicates the observation is no longer statistically significant.
2,3 Specifically, we first developed an example of a hypothetical unmeasured confounder, assuming its strength to be equal to the strongest confounder observed in our data, and calculated the bias factors across various values of prevalence for the confounder in those with and without acetaminophen exposure. Based on this, we calculated the bias-corrected OR and 95% CI for our association of acetaminophen exposure to AKI. Second, we calculated the bias factor at various values of strength for the association of hypothetical confounders to find the ORs that would make the bias-corrected result include the null.
Results
In the primary cohort, we identified a range of magnitude of confounding effects on the exposure and the outcome. The ORs between the observed confounders and acetaminophen exposure (i.e., patients with no acetaminophen compared to with ≥1 acetaminophen dose) ranged from 0.18 to 3.02. The OR between the observed confounders and the outcome of AKI ranged from 0.73 to 2.38. The strongest measured confounder was RACHS score. Compared to patients with low RACHS score of 1, patients with RACHS score ≥3 were 3.02 times more likely to have no acetaminophen, and also had 2.38-fold increased risk for AKI. Assuming that the strength of an unmeasured confounder has similar magnitude as RACHS score, we calculated the bias factor at various values of prevalence of the confounder, and corrected the observed OR of 2.63 (95% CI, 1.34-5.15). The bias-corrected OR was 2.09 (95% CI, 1.07-4.09) under the worst-case scenario, which was obtained at the prevalence of an unmeasured confounder of 0.56 in the no acetaminophen group and 0.3 in the ≥1 acetaminophen dose group.
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For the second sensitivity analysis, we used various values of parameters including extreme values to determine when the study inference could be changed to include the null value, indicating our data were sensitive to that degree of unmeasured confounding. eTable 5 presents the sensitivity analysis results with various values of the ORs between an unmeasured confounder (U) and acetaminophen exposure (E), OR UE , and the ORs between an unmeasured confounder and AKI risk (Y), OR UY . Highlighted in gray are the potential unmeasured confounding effects for which the bias-corrected ORs for the association between AKI and acetaminophen exposure remain statistically significant (i.e., each 95% CI does not include 1). As shown in eTable 5, when values of OR UE and OR UY both exceed 3.0 (dark gray highlight, actual value 3.07), the study inference would be sensitive to this unobserved confounder.
Discussion
In our first sensitivity analysis, the bias-corrected 95% CI did not include the null. Thus inclusion of some hypothetical confounder (currently unmeasured) with similar strength to our strongest measured confounder would not change the study inference. Our second sensitivity analysis indicated that a hypothetical confounder must be associated with >3 fold increased odds of receiving no acetaminophen as compared to receiving ≥1 acetaminophen dose and also must also have >3 fold increased odds of AKI risk to explain away our observed OR of 2.63 for AKI and acetaminophen exposure. That is, the joint minimum strength of association that an unmeasured confounder must have with acetaminophen exposure and AKI is >3.07 to make the 95% CI include the null.
In order for an unmeasured variable to be a confounder, it must be associated with both the exposure (acetaminophen) and the outcome (AKI). In this study, patients with no acetaminophen exposure had several indicators of more severe illness than those with one or more acetaminophen dose, including longer cardiopulmonary bypass time, higher red cell distribution width, and higher RACHS scores. These same variables are associated with increased risk for AKI, making them (measured) confounders. It is possible that there are additional variables that are associated with both acetaminophen exposure and AKI. For example, the Pediatric Risk of Mortality III (PRISM III) score is a mortality risk model for pediatric intensive care unit patients. 4 This variable is not available for our study cohort, but may be associated with the likelihood of acetaminophen exposure, as the sickest patients would be expected, based on our data, to have the lowest exposure rates. The association of PRISM III score and AKI has been assessed. In one study of 252 pediatric intensive care unit patients, higher PRISM III score was associated with AKI with an OR of 1.21 (95% CI 1.11-1.31) after adjusting for age, infection, sepsis, shock, cardiac disease, and mechanical ventilation. 5 Based on the sensitivity analyses, even if PRISM III score was associated with the outcome of AKI with an OR of 1.5 and was associated with an OR of 6.0 for acetaminophen exposure (nearly double the OR observed for RACHS score and acetaminophen exposure), our study findings would remain statistically significant with adjustment for this variable. While no analysis can completely rule out a significant impact of unmeasured confounding, we believe it is unlikely that an additional unmeasured variable has sufficient strength of association to both the exposure and outcome to make our findings statistically insignificant.
In summary, under a wide range of OR UY and OR UE , our study conclusions are not sensitive to unmeasured confounders. For typical values reported in observation studies in the range of 1.2 to 3, our study conclusion is robust. 
